| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/08/2006 | WO2003076571A3 Cancer-linked gene as target for chemotherapy |
| 06/08/2006 | US20060123498 Paks as modifiers of the chk pathway and methods of use |
| 06/08/2006 | US20060122390 Boronic ester and acid compounds, synthesis and uses |
| 06/08/2006 | US20060122387 Derivatives of chromen-2-one as inhibitors of vegf production in mammalian cells |
| 06/08/2006 | US20060122374 Albumin-fused anti-angiogenesis peptides |
| 06/08/2006 | US20060122370 Specific binding agents of human angiopoietin-2 |
| 06/08/2006 | US20060122269 Compounds that abrogate DNA damage induced cell cycle G2 checkpoint and/or augment anti-cancer activity of DNA-damaging treatments |
| 06/08/2006 | US20060122268 Such as N1-(1-cyanocyclopropyl)-4-fluoro-N2-((1S)-2,2,2-trifluoro-1-(4' -(methylsulfonyl)-1,1'-biphenyl-4-yl) ethyl)-L-leucinamide; for treating osteoporosis and other bone loss disorders |
| 06/08/2006 | US20060122260 Intermediates for aromatic polyketides as selective anticancer and antiviral agents |
| 06/08/2006 | US20060122259 Immobilization of taxane; anticancer, antitumor agents |
| 06/08/2006 | US20060122249 Condensed heterocyclic pyrazole derivatives as kinase inhibitors |
| 06/08/2006 | US20060122245 Novel inhibitors of IMPDH enzyme |
| 06/08/2006 | US20060122244 Hypoglycemic agents; antidiabetic agentys; side effect reduction; cardiovascular disorders; anticancer agents |
| 06/08/2006 | US20060122242 2-Aryloxy-2-arylalkanoic acids for diabetes and lipid disorders |
| 06/08/2006 | US20060122241 Novel macrocycles for the treatment of cancer diseases |
| 06/08/2006 | US20060122239 Lipid diseases; metabolism diosrders; antiproliferative agents |
| 06/08/2006 | US20060122234 Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| 06/08/2006 | US20060122221 N-[4-methyl-3-(3-piperidin-4-yl-1,2-benzisoxazol-6-yl)phenyl]-2-pyrrolidin-1-ylisonicotinamide; rheumatoid arthritis |
| 06/08/2006 | US20060122215 Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-C]pyridine derivatives for the treatment of obesity |
| 06/08/2006 | US20060122207 Imidazol derivatives as Raf kinase inhibitors |
| 06/08/2006 | US20060122199 anti-invasive agent for use in the containment and/or treatment of solid tumour disease; little activity against VEGF receptor tyrosine kinase; synergistic use with other anticancer agents; 4-(5-chloro-2,3-methylenedioxypyrid-4-ylamino)-6-methoxy-7-[3-(4-prop-2-ynylpiperazin-1-yl)propoxy]quinazoline |
| 06/08/2006 | US20060122186 Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia |
| 06/08/2006 | US20060122184 Cyanomethyl derivatives as cysteine protease inhibitors |
| 06/08/2006 | US20060122183 Synergistic; side effect reduction; melanomas; toxicity; 2,5-Dimethoxythiobenzoic Acid N-methylhydrazine; anticancer |
| 06/08/2006 | US20060122176 such as 5-(1,3-benzodioxol-5-ylmethylene)-1,3-thiazolidine-2,4-dione, used for the treatment and/or prophylaxis of autoimmune, cardiovascular or neurodegenerative disorders, inflammatory or kidney diseases, bacterial or viral infections, platelet aggregation, cancer, transplant rejection or lung injuries |
| 06/08/2006 | US20060122171 5-[(1-Ethylpiperidin-4-yl)amino]-3-[(3-fluorophenyl)(1H-imidazol-2-yl)methylidene]-1,3-dihydro-2H-indol-2-one; antiproliferative agents; modulating cell differentiation,migration, and chemoinvasion; endothelial growth factor-modulated diseases; antiarthritic agents; graft versus host diseases |
| 06/08/2006 | US20060122163 adding temozolomide with dissolution enhancing agent is selected from L-histidine, L-threonine, L-asparagine, L-serine, and L-glutamine; freeze drying |
| 06/08/2006 | US20060122161 Methods for treating or preventing cancer by preventing, inhibiting, or arresting cell cycling |
| 06/08/2006 | US20060122155 Carbacyclic phosphatidic acid derivative |
| 06/08/2006 | US20060122144 Treats neoplastic disorders, infections from fungal or fungal-like organisms and other parasites |
| 06/08/2006 | US20060122141 For treatment of endocrine-regulated tumors, for example, breast, prostate, ovarian and colon cancers |
| 06/08/2006 | US20060122119 Peptides for use in antitumor immunotherapy |
| 06/08/2006 | US20060122107 Method of modulating cellular activity and molecules for use therein |
| 06/08/2006 | US20060121612 Apparatus for introducing biological material, method of introducing biological material and magnetic support for introducing biological material |
| 06/08/2006 | US20060121529 CpG receptor (CpG-R) and methods relating thereto |
| 06/08/2006 | US20060121526 Method of determining a chemotherapeutic regimen based on ERCC1 and TS expression |
| 06/08/2006 | US20060121514 Prostacyclin-stimulating Factor-2 |
| 06/08/2006 | US20060121454 diagnosis and treatment of carcinomas, especially breast cancers |
| 06/08/2006 | US20060121180 Using electrochemical solution containing metal compound and bioactive materials; contacting substrate |
| 06/08/2006 | US20060121132 TNF-alpha production inhibitor comprising kavalactone as an active ingredient |
| 06/08/2006 | US20060121119 Process for producing nanoparticles of paclitaxel and albumin |
| 06/08/2006 | US20060121117 Anti-angiogenic compositions and methods of use |
| 06/08/2006 | US20060121107 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same |
| 06/08/2006 | US20060121088 delivering to an external portion of the body passageway a therapeutic agent such as an antiangiogenic factor from a thread; treating stenosis or restenosis for example |
| 06/08/2006 | US20060121041 Gpcs as modifiers of the irrtk p21 pathways and methods of use |
| 06/08/2006 | US20060121030 Use of cd 137 antagonists for the treatment of tumors |
| 06/08/2006 | US20060121029 Method and composition for regulating the activity of regulatory t cells |
| 06/08/2006 | US20060121028 Variant IgG3 RITUXAN and therapeutic uses thereof |
| 06/08/2006 | US20060121015 Probiotic bifidobacterium strains |
| 06/08/2006 | US20060121010 Chorionic gonadotropin DNA vaccines and methods |
| 06/08/2006 | US20060120996 Vaccine immunotherapy for immune suppressed patients |
| 06/08/2006 | US20060120985 Novel ampiphilic derivatives of alpha-c-phenyl-n-tert-butyl nitrone |
| 06/08/2006 | DE20122582U1 Zubereitung für Restenoseprophylaxe Preparation for prophylaxis of restenosis |
| 06/08/2006 | DE102004057595A1 Substituierte Pteridine zur Behandlung von entzündlichen Erkrankungen Substituted pteridines for the treatment of inflammatory diseases |
| 06/08/2006 | CA2738383A1 Bicyclic amides as kinase inhibitors |
| 06/08/2006 | CA2610347A1 Alpha-carbolines as cdk-1 inhibitors |
| 06/08/2006 | CA2591301A1 Laminin receptor binding molecule |
| 06/08/2006 | CA2590334A1 Methods of using [3.2.0] heterocyclic compounds and analogs thereof |
| 06/08/2006 | CA2589885A1 Biomarkers for pre-selection of patients for anti-igf1r therapy |
| 06/08/2006 | CA2589824A1 Nanoparticulate benzothiophene formulations |
| 06/08/2006 | CA2589770A1 N-substituted benzimidazolyl c-kit inhibitors and combinatorial benzimidazole library |
| 06/08/2006 | CA2589638A1 7-membered ring compound and method of production and pharmaceutical application thereof |
| 06/08/2006 | CA2589535A1 Perfluorocarbon liquids as carcinogen |
| 06/08/2006 | CA2589484A1 Methods of using temozolomide formulation intrathecally in the treatment of cancers |
| 06/08/2006 | CA2588980A1 Vasopressin-binding l-nucleic acid |
| 06/08/2006 | CA2588923A1 Compositions and methods for treating neoplastic diseases |
| 06/08/2006 | CA2587266A1 Substituted pteridines for treating inflammatory diseases |
| 06/08/2006 | CA2586796A1 [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases |
| 06/08/2006 | CA2584163A1 Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof |
| 06/08/2006 | CA2580801A1 Naturally occuring igm antibodies that bind lymphocytes |
| 06/07/2006 | EP1666880A1 Screening method |
| 06/07/2006 | EP1666600A1 Methods for enhancing the efficacy of cancer therapy |
| 06/07/2006 | EP1666594A2 Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer |
| 06/07/2006 | EP1666589A1 Process for producing cytotoxic lymphocytes |
| 06/07/2006 | EP1666500A1 Use of trifunctionel antibodies to reduce the risk for GvHD in allogeneic antitumor cell therapy |
| 06/07/2006 | EP1666499A2 Novel inhibitors of vascular endothelial growth factor activity, their uses and processes for their production |
| 06/07/2006 | EP1666498A2 Soluble CTLA4 molecules, compositions comprising said molecules and uses thereof |
| 06/07/2006 | EP1666497A2 Polypeptide, nucleic acid encoding it, and their use for the diagnosis of cancer |
| 06/07/2006 | EP1666493A1 Secreted and transmembrane polypeptides and nucleic acids ancoding the same |
| 06/07/2006 | EP1666492A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666491A1 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 06/07/2006 | EP1666485A1 Novel indolopyrrolocarbazole derivative with antitumor activity |
| 06/07/2006 | EP1666481A2 Optical resolution of (1-benzyl-4-methylpiperidin-3-yl)-methylamine and the use thereof for the preparation of pyrrolo[2,3]pyrimidine derivatives as protein kinases inhibitors |
| 06/07/2006 | EP1666480A1 Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. |
| 06/07/2006 | EP1666469A1 Plasminogen activator inhibitor-1 inhibitor |
| 06/07/2006 | EP1666092A2 Drug combination comprising a fatty acid and a uridine compound. |
| 06/07/2006 | EP1666071A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666070A1 Preparation for the prophylaxis of restenose |
| 06/07/2006 | EP1666064A1 Remedy for diseases associated with immunoglobulin gene translocation |
| 06/07/2006 | EP1666060A1 Adjuvant systems and vaccines |
| 06/07/2006 | EP1666055A1 Method for treating oncological, virulent and somatic diseases, method for controlling treatment efficiency, pharmaceutical agents and composition for carrying out said treatment |
| 06/07/2006 | EP1666052A1 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 06/07/2006 | EP1666047A1 Pharmaceutical compositions comprising nitric oxide-releasing pyrrolidones |
| 06/07/2006 | EP1666046A1 Use of n-acetyl-d-aminoglycosamine in preparation of drugs for the treatment of cacer and metastasis |
| 06/07/2006 | EP1666045A1 Sphingomyelin containing preparation for the enhancement of tumor therapy and for the treatment of rheumatoid arthritis |
| 06/07/2006 | EP1666039A1 Use of L-alpha-lysophosphatidylcholine inhibitors to prevent inflammation |
| 06/07/2006 | EP1666035A1 Medicinal composition for treatment for fatty liver or liver disease |
| 06/07/2006 | EP1666031A1 Composition containing nanoparticles containing water-soluble basic drug encapsulated therein |
| 06/07/2006 | EP1666028A1 Dry powder compositions having improved dispersivity |
| 06/07/2006 | EP1664798A2 Non-peptide agonists and antagonists of adrenomedullin and gastrin releasing peptide |